Literature DB >> 10823119

The role of EBV in post-transplant malignancies: a review.

P Hopwood1, D H Crawford.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10823119      PMCID： PMC1731174          DOI： 10.1136/jcp.53.4.248

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  82 in total

1.  Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth.

Authors:  N Lewin; P Aman; M G Masucci; E Klein; G Klein; B Oberg; H Strander; W Henle; G Henle
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

2.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

3.  Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis.

Authors:  R N Sawyer; A S Evans; J C Niederman; R W McCollum
Journal:  J Infect Dis       Date:  1971-03       Impact factor: 5.226

Review 4.  In vivo models for Epstein-Barr virus (EBV)-associated B cell lymphoproliferative disease (BLPD).

Authors:  I Johannessen; D H Crawford
Journal:  Rev Med Virol       Date:  1999 Oct-Dec       Impact factor: 6.989

5.  Studies on long-term T-cell-mediated immunity to Epstein-BArr virus in immunosuppressed renal allograft recipients.

Authors:  D H Crawford; J M Edwards; P Sweny; A V Hoffbrand; G Janossy
Journal:  Int J Cancer       Date:  1981-12       Impact factor: 7.396

6.  Induction of replication of Epstein-Barr virus DNA by 12-O-tetradecanoyl-phorbol-13-acetate. II. Inhibition by retinoic acid and 9-(2-hydroxyethoxymethyl) guanine.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  Virology       Date:  1981-05       Impact factor: 3.616

7.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

8.  Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.

Authors:  H Wakasugi; L Rimsky; Y Mahe; A M Kamel; D Fradelizi; T Tursz; J Bertoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

9.  Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis.

Authors:  E Svedmyr; I Ernberg; J Seeley; O Weiland; G Masucci; K Tsukuda; R Szigeti; M G Masucci; H Blomogren; W Berthold
Journal:  Clin Immunol Immunopathol       Date:  1984-03

10.  Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

Authors:  M Ho; G Miller; R W Atchison; M K Breinig; J S Dummer; W Andiman; T E Starzl; R Eastman; B P Griffith; R L Hardesty
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226
View more
  17 in total

1.  Cervical cancer.

Authors:  P J van Diest; H Holzel
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

2.  Electronic publishing and internet learning.

Authors:  P J van Diest; H Holzel; M Reid; M Crook; G Spickett
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

3.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

4.  Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.

Authors:  Donna Hochberg; Tatyana Souza; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 5.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 6.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 7.  Biology and disease associations of Epstein-Barr virus.

Authors:  D H Crawford
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

8.  CD34+ cord blood cell-transplanted Rag2-/- gamma(c)-/- mice as a model for Epstein-Barr virus infection.

Authors:  Mario Cocco; Cristiana Bellan; Roxane Tussiwand; Davide Corti; Elisabetta Traggiai; Stefano Lazzi; Susanna Mannucci; Lucio Bronz; Nazzareno Palummo; Chiara Ginanneschi; Piero Tosi; Antonio Lanzavecchia; Markus G Manz; Lorenzo Leoncini
Journal:  Am J Pathol       Date:  2008-10-09       Impact factor: 4.307

9.  Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines.

Authors:  Sumita Bhaduri-McIntosh; Marisa J Rotenberg; Benjamin Gardner; Marie Robert; George Miller
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

10.  Primary CD56+ NK/T-cell lymphoma of the rectum accompanied with refractory ulcerative colitis.

Authors:  Kazuki Kakimoto; Takuya Inoue; Takashi Nishikawa; Kumi Ishida; Ken Kawakami; Takanori Kuramoto; Yosuke Abe; Eijiro Morita; Naoko Murano; Ken Toshina; Mitsuyuki Murano; Eiji Umegaki; Yutaro Egashira; Junji Okuda; Nobuhiko Tanigawa; Ichiro Hirata; Ken-Ichi Katsu; Kazuhide Higuchi
Journal:  J Gastroenterol       Date:  2008-07-23       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.